Citation Impact
Citing Papers
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2012 Standout
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
2011
Liraglutide: the therapeutic promise from animal models
2010
The Cardiovascular Biology of Glucagon-like Peptide-1
2016
Novel therapeutic targets for the treatment of heart failure
2011
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
2015 Standout
Myocardial ischemia-reperfusion injury: a neglected therapeutic target
2013 Standout
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
2014
Cell Biology of Ischemia/Reperfusion Injury
2012 Standout
The potential effects of anti-diabetic medications on myocardial ischemia–reperfusion injury
2011
Cardiovascular effects of gliptins
2013
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
2010
GLP-1 agonist-based therapies: An emerging new class of antidiabetic drug with potential cardioprotective effects
2009
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
2019 Standout
Incretins as a novel therapeutic strategy in patients with diabetes and heart failure
2012
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
2013 Standout
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
2012
A within-trial cost-effectiveness analysis of primary care referral to a commercial provider for weight loss treatment, relative to standard care—an international randomised controlled trial
2012 Standout
The potential for renoprotection with incretin-based drugs
2014
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2012 Standout
Peptide therapeutics: current status and future directions
2014 Standout
The Discovery and Development of Liraglutide and Semaglutide
2019
A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
2010
Dipeptidyl peptidase IV inhibitors as novel regulators of vascular disease
2017
Type 2 diabetes mellitus
2015 Standout
Cardiovascular Effects of Glucagonlike peptide–1 Agonists
2011
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
2013 Standout
Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat
2013
Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety
2012
Cardiovascular Biology of the Incretin System
2012
Endoplasmic Reticulum Stress As a Therapeutic Target in Cardiovascular Disease
2010
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
2010
Once-Weekly Semaglutide in Adults with Overweight or Obesity
2021 Standout
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
2009
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
Mechanisms of Diabetic Complications
2013 Standout
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial
2013
Reactive Oxygen Species in Metabolic and Inflammatory Signaling
2018 Standout
Cardiovascular Actions of Incretin-Based Therapies
2014
GPR119 Is Essential for Oleoylethanolamide-Induced Glucagon-Like Peptide-1 Secretion From the Intestinal Enteroendocrine L-Cell
2009
Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
2012 Standout
GLP-1 receptor agonists today
2011
Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus
2014
Works of Judith Hoefer being referenced
Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
2008